CTX110 (NCT04035434), targeting CD19+ cancers (B cell leukemias and lymphomas), and CTX130 (NCT04502446 and NCT04438083), targeting CD70+ cancers (T cell lymphomas and renal cell carcinomas), both knockout the β2M gene, a subunit of the major histocompatibility complex class 1 (MHC-I) subunit. This evidence concerns the gene CD19 and lymphoma.